Foreign Corrupt Practices Act: Investigations Dataset

Investigation Name: Investigation into Teva's Activities in Latin America

Trend: None

Type of investigation: Internal, SEC, DOJ

Other Agencies Investigating/Assisting with SEC/DOJ Investigation:

Israeli Government Agency
Russian Government Agency

Whistleblower: Unknown

Summary

Teva Pharmaceutical Industries Ltd. ("Teva"), an Israeli multinational pharmaceutical company, is one of the largest generic drug manufacturers in the world. Its stock is traded on the NYSE.

On July 9, 2012, Teva received a subpoena from the SEC requesting documents pertaining to the company's FCPA compliance in Latin America. In October 2012, the company also received informal document requests from the DOJ.

After receiving the SEC subpoena, Teva instituted an internal investigation into business practices with possible FCPA implications. During the course of the internal investigation, Teva discovered other possible FCPA issues in Russia and Eastern Europe.

On December 22, 2016, Teva entered into a Deferred Prosecution Agreement with the DOJ to resolve alleged FCPA violations in Russia, the Ukraine, and Mexico. That same day, Teva's wholly owned subsidiary, Teva LLC, pled guilty to a one count criminal Information charging conspiracy to violate the anti-bribery provisions of the FCPA. The SEC also filed a civil complaint against Teva on December 22, 2016, and the company consented to a final judgment in that action.

Protected Content

Please Log In or Sign Up for a free account to access restricted features of the Clearinghouse website, including the Advanced Search form and the full case pages.

When you sign up, you will have the option to save your search queries performed on the Advanced Search form.

| Investigations Dataset

Investigations Dataset

Information & Summary

Investigation into Teva's Activities in Latin America

Information & Summary

Protected Content